Coya Therapeutics (COYA) Corporate presentation summary

Investment highlights and market opportunity

• Focus on ALS, FTD, and Alzheimer's, all with high unmet medical need and significant market potential exceeding $10B combined.

• COYA 302 and COYA 303 are novel combination therapies targeting Treg dysfunction, with ongoing and planned Phase 2 studies.

• Strategic partnerships include Dr. Reddy's (up to $700M in milestones, $10M investment) and ADDF ($5M for FTD trial).

• Estimated cash runway of $47M through 2H 2027.

Scientific rationale and therapeutic approach

• Combination therapies leverage validated Treg biology, recognized by a Nobel Prize, and are supported by independent scientific evidence.

• Treg dysfunction is linked to neurodegeneration; restoring Treg function reduces neuroinflammation and improves clinical outcomes.

• COYA 302 (LD IL-2 + CTLA4-Ig) and COYA 303 (LD IL-2 + GLP-1 RA) aim to rebalance immune regulation and provide neuroprotection.

Clinical and preclinical data

• Investigator-initiated trials in ALS and FTD showed stabilization or improvement in clinical scores and Treg function over 22–48 weeks.

• Early clinical validation includes improved or stable ALSFRS-R scores and cognitive stability in FTD.

• Preclinical data in Alzheimer's models show reduced neuroinflammation and enhanced Treg function with COYA 303.